Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells

被引：4

作者：

Sakai, Osamu ^{[1
]}

Ogino, Shoji ^{[2
]}

Tsukui, Toshihiro ^{[2
]}

Igase, Masaya ^{[1
]}

Mizuno, Takuya ^{[1
]}

机构：

[1] Yamaguchi Univ, Joint Grad Sch Vet Med, Lab Mol Diagnost & Therapeut, 1677-1 Yoshida, Yamaguchi 7538515, Japan

[2] Nippon Zenyaku Kogyo Co Ltd, Koriyama, Fukushima 9630196, Japan

来源：

JOURNAL OF VETERINARY MEDICAL SCIENCE | 2021年 / 83卷 / 10期

关键词：

adoptive immunotherapy; canine; CD20; chimeric antigen receptorT cell; monoclonal antibody; RITUXIMAB; LYMPHOMA; THERAPY; MODEL; DOGS;

D O I：

10.1292/jvms.21-0326

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

Chimeric antigen receptor (CAR) CAR-T cell therapy targeting CD20 can be a novel adoptive cell therapy for canine patients with B-cell malignancy. After injection of the CAR-T cells in vivo, monitoring circulating CAR-T cells is essential to prove in vivo persistence of CAR-T cells. In this study, we developed a novel monoclonal antibody against canine CD20 CAR, whose single-chain variable fragment was derived from the our previously reported anti-canine CD20 therapeutic antibody. Furthermore, we proved that this monoclonal antibody can detect therapeutic anti-canine CD20 chimeric antibody in the serum from healthy beagle dogs injected with the therapeutic antibody for safety study. This monoclonal antibody is a useful tool for monitoring both canine CD20-CAR-T cells and anti-canine CD20 therapeutic antibody for canine lymphoma.

引用

页码：1495 / 1499

页数：5

共 21 条

[1] Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma [J].

Berinstein, NL ;

Grillo-Lopez, AJ ;

White, CA ;

Bence-Bruckler, I ;

Maloney, D ;

Czuczman, M ;

Green, D ;

Rosenberg, J ;

McLaughlin, P ;

Shen, D .

ANNALS OF ONCOLOGY, 1998, 9 (09) :995-1001

[2] CAR T cell therapy for B-cell lymphomas [J].

Chavez, Julio C. ;

Locke, Frederick L. .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (02) :135-146

[3] Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation [J].

Guedan, Sonia ;

Posey, Avery D., Jr. ;

Shaw, Carolyn ;

Wing, Anna ;

Da, Tong ;

Patel, Prachi R. ;

McGettigan, Shannon E. ;

Casado-Medrano, Victoria ;

Kawalekar, Omkar U. ;

Uribe-Herranz, Mireia ;

Song, Decheng ;

Melenhorst, J. Joseph ;

Lacey, Simon F. ;

Scholler, John ;

Keith, Brian ;

Young, Regina M. ;

June, Carl H. .

JCI INSIGHT, 2018, 3 (01)

[4] Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential [J].

Ito, Daisuke ;

Brewer, Susan ;

Modiano, Jaime F. ;

Beall, Melissa J. .

LEUKEMIA & LYMPHOMA, 2015, 56 (01) :219-225

[5] Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications [J].

Ito, Daisuke ;

Frantz, Aric M. ;

Modiano, Jaime F. .

VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2014, 159 (3-4) :192-201

[6] Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response [J].

Jaeger, Ulrich ;

Fridrik, Michael ;

Zeitlinger, Markus ;

Heintel, Daniel ;

Hopfinger, Georg ;

Burgstaller, Sonja ;

Mannhalter, Christine ;

Oberaigner, Wilhelm ;

Porpaczy, Edit ;

Skrabs, Cathrin ;

Einberger, Christine ;

Drach, Johannes ;

Raderer, Markus ;

Gaiger, Alexander ;

Putman, Monique ;

Greil, Richard .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (09) :1431-1438

[7] The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine [J].

Jain, Saurabh ;

Aresu, Luca ;

Comazzi, Stefano ;

Shi, Jianguo ;

Worrall, Erin ;

Clayton, John ;

Humphries, William ;

Hemmington, Sandra ;

Davis, Paul ;

Murray, Euan ;

Limeneh, Asmare A. ;

Ball, Kathryn ;

Ruckova, Eva ;

Muller, Petr ;

Vojtesek, Borek ;

Fahraeus, Robin ;

Argyle, David ;

Hupp, Ted R. .

PLOS ONE, 2016, 11 (02)

[8] Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 [J].

Kochenderfer, James N. ;

Wilson, Wyndham H. ;

Janik, John E. ;

Dudley, Mark E. ;

Stetler-Stevenson, Maryalice ;

Feldman, Steven A. ;

Maric, Irina ;

Raffeld, Mark ;

Nathan, Debbie-Ann N. ;

Lanier, Brock J. ;

Morgan, Richard A. ;

Rosenberg, Steven A. .

BLOOD, 2010, 116 (20) :4099-4102

[9] T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial [J].

Lee, Daniel W. ;

Kochenderfer, James N. ;

Stetler-Stevenson, Maryalice ;

Cui, Yongzhi K. ;

Delbrook, Cindy ;

Feldman, Steven A. ;

Fry, Terry J. ;

Orentas, Rimas ;

Sabatino, Marianna ;

Shah, Nirali N. ;

Steinberg, Seth M. ;

Stroncek, Dave ;

Tschemia, Nick ;

Yuan, Constance ;

Zhang, Hua ;

Zhang, Ling ;

Rosenberg, Steven A. ;

Wayne, Alan S. ;

Mackall, Crystal L. .

LANCET, 2015, 385 (9967) :517-528

[10] Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers [J].

Mata, Melinda ;

Gottschalk, Stephen .

MOLECULAR THERAPY, 2016, 24 (09) :1511-1512

← 1 2 3 →